StreetAlpha.app
Home › Stocks › ALLO

Allogene Therapeutics, Inc. (ALLO)

Healthcare
$0.74
▼ −7.79%
LAST CLOSE · NOV 17

Allogene Therapeutics develops engineered T cell treatments from healthy donor cells for cancer and autoimmune diseases. It last closed at $0.74 on Nov 17, down 7.79% on the day. ALLO last reported earnings on Wed, Aug 12, 2026. In the past 30 days there were 4 dark pool prints totaling $1.5M, the largest $1.1M.

AI Auto Pilots
Is ALLO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$4.6M
Net income
−$174.5M
−3760.0% margin
EPS (diluted)
−$0.61
Free cash flow
−$108.8M
−2345.0% margin
Valuation
Market cap
$257.8M
346.5M shares
P/E
–
No P/E while losing money
Price to sales
55.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$29.3M
At Sep 30
Shareholder equity
$392.6M
Shares outstanding
346.5M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $114.1M$114.1MFY2021FY2022: $156K$156KFY2022FY2023: $95K$95KFY2023FY2024: $22K$22KFY2024FY2025: $0$0FY2025

From ALLO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Last report
Aug 12
2026 · After the close (AMC)
Reported EPS
-$0.13
vs -$0.16 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±13.3%
Priced in before that report
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated ALLO in the past 90 days.
Average 12-month target
No price targets on ALLO in the past 90 days.
Latest rating changes
CitizensReiterated
Aug 17Buy$6
DateFirmActionRatingPrice target
Aug 17CitizensReiteratedBuy$6
Loading…

Technical Analysis

ALLO · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 46% below its 20 day and 84% below its 50 day average. It is 161% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 21), oversold. The nearest support is the 52 week low at $0.74, and the nearest resistance the Pivot at $0.77.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 12.7%/day
Key levels
$4.4652 week high+502.7%
$1.94200 day average+162.2%
$1.67100 day average+125.7%
$1.3750 day average+85.1%
$1.37Swing high (Oct 21)+85.1%
$1.0820 day average+45.9%
$0.79Pivot R1+6.8%
$0.77Pivot+4.1%
$0.7452 week low+0.0%
$0.74Last close
$0.72Pivot S1−2.7%
Indicators
RSI (14)21.38Oversold below 30Oversold
MACD-0.17Below its signal lineBearish
Stochastic3.4Near the bottom of its rangeOversold
ADX (14)48.3Strong downtrend
Williams %R-99.5Oversold below −80, overbought above −20Oversold
CCI (20)-145.5Oversold below −100, overbought above 100Oversold
Rate of change−33.6%Change over 10 sessionsBearish
ATR (14)$0.09Typical daily range, 12.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ALLO

What happened before

See how ALLO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ALLO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ALLO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ALLO in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
4
Notional
$1.5M
Largest print
$1.1M
Loading…

ALLO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼80 buying vs 109 selling
  • ▼Held by funds -2.6 pts
  • ▼Funds holding -12
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding197209−5.7%
In funds' top 10440.0%
Held by funds87.7%90.3%−2.6 pts
New / increased25 / 5532 / 99−38.9%
Reduced / sold out75 / 3451 / 30+34.6%
Put/call ratio0.080.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ALLO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALLO is in one of them and how their past ALLO trades turned out.

ALLO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALLO in an article yet. Here's the latest on the wider market.

About Allogene Therapeutics

Allogene Therapeutics is a biotechnology company based in South San Francisco, California, that develops engineered T cell treatments for cancer and autoimmune diseases. Its treatments are made from healthy donor cells, so they can be prepared ahead of time and given to any eligible patient rather than made from each patient's own cells. Its main candidates target lymphoma, kidney cancer and autoimmune conditions such as lupus, and they are in clinical trials with patients as the intended users.

Headquarters
South San Francisco, CA